Table 2.
MS history (N = 309).
| Clinical phenotype | Relapsing remitting MS (RRMS) | 277 (89.6) |
| Secondary progressive MS (SPMS) | 26 (8.4) | |
| Primary progressive MS (PPMS) | 6 (1.9) | |
| MS disease duration, years | 5.0 (2.0 – 10.0) | |
| Last available EDSS | 1.5 (1.0 – 3.0) | |
| Multiple Sclerosis Severity Scores (MSSS) | < 7 | 267 (86.4) |
| ≥ 7 | 42 (13.6) | |
| In treatment | 283 (91.6) | |
| Treatment duration, months | 19.0 (9.0 – 41.0) | |
| Line of treatment | 1st line | 163 (52.8) |
| 2nd line | 120 (38.8) | |
| MS treatment | Fingolimod | 68 (22.0) |
| Interferon | 62 (20.1) | |
| Ocrelizumab | 43 (13.9) | |
| Teriflunomide | 43 (13.9) | |
| Dimethyl fumarate | 30 (9.7) | |
| Glatiramer acetate | 27 (8.7) | |
| None | 26 (8.4) | |
| Natalizumab | 7 (2.4) | |
| Alemtuzumab | 1 (0.3) | |
| Rituximab | 1 (0.3) | |
| Other | 1 (0.3) | |
| Treatment interrupted | 44/283 (15.5) | |
| Reason for interruption | For Covid-19 infection | 30/44 (68.2) |
| Other/Not specified | 6/44 (13.6) | |
| Patient's decision | 5/44 (11.4) | |
| Other* | 3/44 (6.8) | |
| Use of methylprednisolone previous 1 mount | Yes | 30 (9.7) |
Please note that data are reported as median (IQR) and n(%) within the table, whereas in the main manuscript data are reported with minimum and maximum values
⁎
Adverse event / side effect, lack of efficacy, pregnancy or pregnancy planning